We use cookies on accura.dk

accura.dk uses cookies to improve the user-friendliness and functionality. By using our website, you consent to our use of cookies. Read more about cookies at accura.dk. Enjoy.

Read more about our cookie policy and instructions to delete cookies

;

Voluntary public offer for Veloxis in an amount of DKK 8.9bn


Case info

The majority shareholders of Veloxis Pharmaceuticals A/S ("Veloxis") have undertaken to accept a conditional, voluntary public offer from Asahi Kasei Pharma Denmark A/S.

The offer to purchase all of the issued and outstanding shares and warrants in Veloxis corresponds to a total price of approx. DKK 8.9bn if all shares are sold and all warrants are acquired.

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. The shares in Veloxis are admitted to trading and official listing on Nasdaq Copenhagen. Lundbeckfond Invest A/S and Novo Holdings A/S each holds more than 40% of the shares in Veloxis.

Asahi Kasei Pharma Denmark A/S is a subsidiary of Asahi Kasei Corporation, a Japanese public corporation listed on the Tokyo Stock Exchange. The group comprises several companies within the health care sector, including the hospitals.

Veloxis' board of directors has unanimously resolved to recommend that the shareholders of Veloxis vote to accept the offer.

Jacob Vinther, Kim Toftgaard, Lars Hagbard Grønkjær and Ann-Sofie Trampe Jarløv has advised Lundbeckfond Invest A/S in connection with the transaction.


Contact

Jacob Vinther
Jacob Vinther

Partner, Attorney-at-Law, LL.M.

Phone: +45 3945 2888
Mobile: +45 3078 6688
jacob.vinther@accura.dk

Kim Toftgaard
Kim Toftgaard

Partner, Attorney-at-Law, LL.M.

Mobile: +45 3078 6602
kim.toftgaard@accura.dk

Lars Hagbard Grønkjær
Lars Hagbard Grønkjær

Partner, Attorney-at-Law

Mobile: +45 3078 6681
lars.gronkjaer@accura.dk


Accura's recent cases

We advise in connection with the largest and most complex transactions on the market.

Read a selection of our cases here.

Accura's recent cases

Accura's M&A Team

Accura's M&A Team